Axial Spondyloarthritis : Reshape the Future-From the "2022 GISEA International Symposium"
The term "axial spondyloarthritis" (axSpA) refers to a group of chronic rheumatic diseases that predominantly involve the axial skeleton and consist of ankylosing spondylitis, reactive arthritis, arthritis/spondylitis associated with psoriasis (PsA) and arthritis/spondylitis associated with inflammatory bowel diseases (IBD). Moreover, pain is an important and common symptom of axSpA. It may progress to chronic pain, a more complicated bio-psychosocial phenomena, leading to a significant worsening of quality of life. The development of the axSpA inflammatory process is grounded in the complex interaction between genetic (such as HLA B27), epigenetic, and environmental factors associated with a dysregulated immune response. Considering the pivotal contribution of IL-23 and IL-17 in axSpA inflammation, the inhibition of these cytokines has been evaluated as a potential therapeutic strategy. With this context, here we discuss the main pathogenetic mechanisms, therapeutic approaches and the role of pain in axSpA from the 2022 International GISEA/OEG Symposium.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 11(2022), 24 vom: 19. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salaffi, Fausto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Axial spondyloarthritis |
|---|
| Anmerkungen: |
Date Revised 26.12.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm11247537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350676755 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350676755 | ||
| 003 | DE-627 | ||
| 005 | 20231226045531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11247537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350676755 | ||
| 035 | |a (NLM)36556152 | ||
| 035 | |a (PII)7537 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salaffi, Fausto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Axial Spondyloarthritis |b Reshape the Future-From the "2022 GISEA International Symposium" |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The term "axial spondyloarthritis" (axSpA) refers to a group of chronic rheumatic diseases that predominantly involve the axial skeleton and consist of ankylosing spondylitis, reactive arthritis, arthritis/spondylitis associated with psoriasis (PsA) and arthritis/spondylitis associated with inflammatory bowel diseases (IBD). Moreover, pain is an important and common symptom of axSpA. It may progress to chronic pain, a more complicated bio-psychosocial phenomena, leading to a significant worsening of quality of life. The development of the axSpA inflammatory process is grounded in the complex interaction between genetic (such as HLA B27), epigenetic, and environmental factors associated with a dysregulated immune response. Considering the pivotal contribution of IL-23 and IL-17 in axSpA inflammation, the inhibition of these cytokines has been evaluated as a potential therapeutic strategy. With this context, here we discuss the main pathogenetic mechanisms, therapeutic approaches and the role of pain in axSpA from the 2022 International GISEA/OEG Symposium | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a axial spondyloarthritis | |
| 650 | 4 | |a pain | |
| 650 | 4 | |a pathogenesis | |
| 650 | 4 | |a therapy | |
| 700 | 1 | |a Siragusano, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Alciati, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Cassone, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Angelo, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Guiducci, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Favalli, Ennio Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Gremese, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Florenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Caporali, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastiani, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraccioli, Gian Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Lapadula, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 11(2022), 24 vom: 19. Dez. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:24 |g day:19 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm11247537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 24 |b 19 |c 12 | ||